v3.25.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows from operating activities:    
Net loss (income) $ (273,911) $ 57,490
Adjustments to reconcile net loss (income) to net cash used in operating activities:    
Share-based compensation 82,178 50,191
Change in fair value of investments 19,125 (15,226)
Change in fair value of debt and liability instruments 2,329 (118,202)
Gain on sale of Telavant net assets 0 (110,387)
Accretion of discount and amortization of premium on marketable securities, net (11,061) 0
Depreciation and amortization 1,098 4,883
Non-cash lease expense 1,943 1,581
Other 11,082 5,576
Changes in assets and liabilities, net of effects from acquisition and divestiture:    
Other current assets 128 (16,334)
Accounts payable (11,745) (25,267)
Accrued expenses (25,000) (37,584)
Operating lease liabilities (478) (1,816)
Other (71) 12,266
Net cash used in operating activities (204,383) (192,829)
Cash flows from investing activities:    
Purchases of marketable securities (1,801,681) 0
Maturities of marketable securities 720,000 0
Purchase of property and equipment (4,035) (965)
Net cash used in investing activities (1,085,716) (965)
Cash flows from financing activities:    
Repayment of debt by subsidiary 0 (1,500)
Payments on principal portion of finance lease obligations 0 (329)
Proceeds from exercise of the Company’s and subsidiary stock options 30,057 2,271
Taxes paid related to net settlement of equity awards (9,532) (12,673)
Repurchase of common shares (208,293) (648,385)
Net cash used in financing activities (187,768) (660,616)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash 815 (2,740)
Net change in cash, cash equivalents and restricted cash (1,477,052) (857,150)
Cash, cash equivalents and restricted cash at beginning of period 2,725,661 6,550,450
Cash, cash equivalents and restricted cash at end of period 1,248,609 5,693,300
Non-cash investing and financing activities:    
Issuance of subsidiary shares in connection with Debt Renegotiation 0 11,647
Other $ 44 $ 113